Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standard-dose versus therapeutic drug monitoring-guided alectinib dosing
2020-001737-13Phase 4Active
- Sponsor
- University Medical Center Groningen
- Start
- Feb 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of alectinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Median progression-free survival in patients with low trough concentration. Started Feb 2022; status: active.
02
Drugs
alectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-001737-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001737-13.